Synthesis and biological evaluation of an anticancer vaccine containing the C-glycoside analogue of the Tn epitope

Francesco Peri, Laura Cipolla, Maria Rescigno, Barbara La Ferla, Francesco Nicotra

Research output: Contribution to journalArticle

Abstract

The C-saccharide analogue of the GalNAc (Tn epitope) has been covalently linked to the T cell epitope peptide OVA using a chemoselective convergent synthetic approach. In this way, a nonhydrolyzable synthetic vaccine was obtained composed by a B epitope conjugated to a T cell epitope. This compound was tested in a proliferation assay with spleen cells from DO11.10 mice. The molecule was recognized by transgenic T cells although at a slightly lower efficiency if compared with the reference peptide OVA. An additional experiment with dendritic cells fixed with glutaraldehyde shows that the glycopeptide can bind to extracellular MHC molecules without need of internalization and processing and that the C-glycoside part does not interfere with TCR recognition. These observations constitute an important starting point for the use of this molecule as vaccine against the Tn-expressing TA3-Ha mouse mammary carcinoma.

Original languageEnglish
Pages (from-to)325-328
Number of pages4
JournalBioconjugate Chemistry
Volume12
Issue number3
DOIs
Publication statusPublished - May 2001

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Fingerprint Dive into the research topics of 'Synthesis and biological evaluation of an anticancer vaccine containing the C-glycoside analogue of the Tn epitope'. Together they form a unique fingerprint.

  • Cite this